Ixiaro®: a new vaccine against Japanese encephalitis

The mosquito-borne Japanese encephalitis virus (JEV) is a major threat to human health in Asia. An estimated 50,000 cases occur in the region, accounting for at least 10,000 deaths and 15,000 cases of neuropsychiatric sequelae. A new purified, inactivated JEV vaccine (IC51, Ixiaro®) has been developed. Since early 2009, the vaccine has been licensed in Australia, the USA and Europe. A series of successful Phase III studies has been published. Results indicate a very good safety and efficacy profile. The vaccine promises to become a modern approach to active immunization against Japanese encephalitis. With the availability of a new product, wider use of Japanese encephalitis vaccine will be prudent in the future, and guidelines and recommendations should be revised.

[1]  M. Holbrook,et al.  Japanese Encephalitis Vaccines. , 2011, Journal of bioterrorism & biodefense.

[2]  C. Klade,et al.  Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study. , 2009, Vaccine.

[3]  H. Kollaritsch,et al.  IC51 Japanese Encephalitis vaccine , 2009, Expert opinion on biological therapy.

[4]  L. Lindquist,et al.  Japanese encephalitis in travelers: review of cases and seasonal risk. , 2009, Journal of travel medicine.

[5]  A. Wilder-Smith,et al.  Expert opinion on vaccination of travelers against Japanese encephalitis. , 2009, Journal of travel medicine.

[6]  C. Klade,et al.  Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. , 2009, Vaccine.

[7]  G. Plosker,et al.  Japanese Encephalitis Vaccine (Inactivated, Adsorbed) [IXIARO®] , 2009, Drugs.

[8]  F. Heinz,et al.  Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. , 2008, Vaccine.

[9]  O. Vapalahti,et al.  Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[10]  W. J. McBride,et al.  Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. , 2008, The Journal of infectious diseases.

[11]  C. Klade,et al.  Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. , 2008, Vaccine.

[12]  T. Jelínek.  Japanese encephalitis vaccine in travelers , 2008, Expert review of vaccines.

[13]  M. Ooi,et al.  A decade of Japanese encephalitis surveillance in Sarawak, Malaysia: 1997–2006 , 2008, Tropical medicine & international health : TM & IH.

[14]  D. Beasley,et al.  Current use and development of vaccines for Japanese encephalitis , 2008, Expert opinion on biological therapy.

[15]  C. Klade,et al.  Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial , 2007, The Lancet.

[16]  A. di Caro,et al.  A case of imported JE acquired during short travel in Vietnam. Are current recommendations about vaccination broader? , 2007, Journal of travel medicine.

[17]  K. L. Wai,et al.  Vaccines for preventing Japanese encephalitis. , 2007, The Cochrane database of systematic reviews.

[18]  I. Kurane,et al.  Japanese encephalitis for a reference to international travelers. , 2007, Journal of travel medicine.

[19]  D. Vaughn,et al.  A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. , 2007, Vaccine.

[20]  T. Solomon.  Control of Japanese encephalitis--within our grasp? , 2006, The New England journal of medicine.

[21]  A. Nisalak,et al.  A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia , 2006, BMC medicine.

[22]  R. Steffen,et al.  Vaccines in travel health: from risk assessment to priorities. , 2006, Journal of travel medicine.

[23]  I. Kurane,et al.  Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. , 2005, Vaccine.

[24]  S. Halstead,et al.  Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study , 2005, The Lancet.

[25]  O. Tsang,et al.  Japanese encephalitis in Hong Kong. , 2005, Hong Kong medical journal = Xianggang yi xue za zhi.

[26]  M. Bista,et al.  Epidemiological situation of Japanese encephalitis in Nepal. , 2005, JNMA; journal of the Nepal Medical Association.

[27]  A. Plesner.  Allergic reactions to Japanese encephalitis vaccine. , 2003, Immunology and allergy clinics of North America.

[28]  F. Guirakhoo,et al.  Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. , 2003, The Journal of infectious diseases.

[29]  M. Ogawa,et al.  Short report: a major genotype of Japanese encephalitis virus currently circulating in Japan. , 2003, The American journal of tropical medicine and hygiene.

[30]  T. Solomon,et al.  Japanese encephalitis vaccine for travelers: exploring the limits of risk. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  S. Halstead,et al.  Efficacy of single-dose SA 14–14–2 vaccine against Japanese encephalitis: a case control study , 2001, The Lancet.

[32]  D. Vaughn,et al.  A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. , 2001, Vaccine.

[33]  D. Vaughn,et al.  Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus. , 2000, Vaccine.

[34]  T. Tsai.  New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. , 2000, Vaccine.

[35]  S. Ritchie,et al.  Japanese encephalitis in north Queensland, Australia, 1998 , 1999, The Medical journal of Australia.

[36]  A. Barrett,et al.  Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. , 1999, Virology.

[37]  A. Barrett,et al.  Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. , 1999, Vaccine.

[38]  S. Halstead,et al.  Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. , 1997, The Journal of infectious diseases.

[39]  Diana M. Novak,et al.  Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  S. Halstead,et al.  Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study , 1996, The Lancet.

[41]  T. Jelínek,et al.  Adverse reactions to Japanese encephalitis vaccine in travellers. , 1996, The Journal of infection.

[42]  T. Matsuishi,et al.  Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains). , 1995, Journal of neurology, neurosurgery, and psychiatry.

[43]  B. Niklasson,et al.  Japanese encephalitis after a 10-day holiday in Bali , 1995, The Lancet.

[44]  H. Yin,et al.  The efficacy of Japanese encephalitis vaccine in Henan, China: a case-control study. , 1994, Southeast Asian Journal of Tropical Medicine and Public Health.

[45]  A. Barrett,et al.  Comparison of nucleotide and deduced amino acid sequence of the 5' non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives. , 1994, The Journal of general virology.

[46]  A K Highsmith,et al.  Surveillance for waterborne disease outbreaks--United States, 1991-1992. , 1993, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[47]  T. Matsuishi,et al.  Acute disseminated encephalomyelitis after Japanese B encephalitis vaccination. , 1992, Pediatric neurology.

[48]  T. Ruff,et al.  Adverse reactions to Japanese encephalitis vaccine , 1991, The Lancet.

[49]  H. Robinson,et al.  Japanese encephalitis vaccine and adverse effects among travellers. , 1991, Canada diseases weekly report = Rapport hebdomadaire des maladies au Canada.

[50]  T. Rønne,et al.  Side-effects with Japanese encephalitis vaccine , 1991, The Lancet.

[51]  R. Rico-Hesse,et al.  Genetic variation of Japanese encephalitis virus in nature. , 1990, The Journal of general virology.

[52]  C. B. Cropp,et al.  Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. , 1990, The Journal of infectious diseases.

[53]  R. DeFraites,et al.  Further experience with Japanese encephalitis vaccine , 1990, The Lancet.

[54]  S. Sucharit,et al.  Vectors of Japanese encephalitis virus (JEV): species complexes of the vectors. , 1989, The Southeast Asian journal of tropical medicine and public health.

[55]  T. Suroso.  Studies on Japanese encephalitis vectors in Indonesia. , 1989, The Southeast Asian journal of tropical medicine and public health.

[56]  R. Ouvrier,et al.  Japanese encephalitis after a two‐week holiday in Bali , 1989, The Medical journal of Australia.

[57]  A. Nisalak,et al.  Protection against Japanese encephalitis by inactivated vaccines. , 1988, The New England journal of medicine.

[58]  T. Tsai,et al.  Serum and cerebrospinal fluid immunoglobulins M, A, and G in Japanese encephalitis , 1988, Journal of clinical microbiology.

[59]  A. Nisalak,et al.  A longitudinal study of Japanese encephalitis in suburban Bangkok, Thailand. , 1987, The Southeast Asian journal of tropical medicine and public health.

[60]  B. Gatus,et al.  A case of Japanese B encephalitis imported into the United Kingdom. , 1983, The Journal of infection.

[61]  R. Edelman,et al.  The effect of dengue virus infection on the clinical sequelae of Japanese encephalitis: a one year follow-up study in Thailand. , 1975, The Southeast Asian journal of tropical medicine and public health.

[62]  R. Edelman,et al.  Clinical sequelae after japanese encephalitis: a one year follow-up study in Thailand. , 1974, The Southeast Asian journal of tropical medicine and public health.

[63]  W. Hammon,et al.  Passive immunity for arbovirus infection. I. Artificially induced prophylaxis in man and mouse for Japanese (B) encephalitis. , 1973, The American journal of tropical medicine and hygiene.

[64]  O. Weaver.  V. Japanese Encephalitis , 1958, Neurology.

[65]  L. Kurland,et al.  Sequelae of Japanese B and mumps encephalitis: recent follow-up of patients affected in 1947-1948 epidemic on Guam. , 1958, The American journal of tropical medicine and hygiene.

[66]  G. Meiklejohn,et al.  Sequelse of Japanese B encephalitis. , 1947, American Journal of Tropical Medicine and Hygiene.

[67]  T. W. Simpson,et al.  Sequelae of Japanese B Encephalitis1,2,3 , 1947 .

[68]  W. Fridman,et al.  Introduction to the field , 1998 .

[69]  R. Harpaz,et al.  Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 1996, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[70]  N. Begg,et al.  Systemic allergic reactions to Japanese encephalitis vaccines. , 1994, Vaccine.

[71]  Tennessee.,et al.  Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[72]  A. Igarashi.  Epidemiology and control of Japanese encephalitis. , 1992, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[73]  C. Rice,et al.  Flavivirus genome organization, expression, and replication. , 1990, Annual review of microbiology.

[74]  J. Stephenson.  Flavivirus vaccines. , 1988, Vaccine.

[75]  T. Umenai,et al.  Japanese encephalitis: current worldwide status. , 1985, Bulletin of the World Health Organization.

[76]  S. R. Prasad,et al.  Isolation of Japanese encephalitis & West Nile viruses from peripheral blood of encephalitis patients. , 1984, The Indian journal of medical research.

[77]  A. Budak.  [Japanese encephalitis]. , 1975, Fel'dsher i akusherka.

[78]  Gubler Mackenzie JS.  Japanese Encephalitis Vaccines ; WHO Position Paper Aug 2006 : Selected references Epidemiology of Japanese Encephalitis , 2022 .